Email Us
Call Us
AUSTIN, Texas – March 24, 2018 – Altogen Labs today detailed the research applications of its validated MOLM-13 xenograft model, a robust platform for evaluating FLT3 and HDAC inhibitors in acute myeloid leukemia.
The published record demonstrates the model’s utility in the resistance setting. A 2017 study used MOLM-13 to evaluate FF-10101, an irreversible FLT3 inhibitor developed specifically to overcome the mutation-based resistance observed with quizartinib, and reported potent, selective FLT3 inhibition even in the presence of resistance mutations. Work by Keegan and colleagues in 2014 evaluated the FLT3/CDK4 dual kinase inhibitor AMG 925 in the same model, finding STAT5/Rb-mediated reduction in xenograft tumor growth and the ability to overcome FLT3 mutation-mediated resistance.
FLT3-mutated AML remains one of the more difficult targets in hematologic oncology precisely because resistance emerges so reliably. Programs designed to address that resistance need a model where resistance biology has been characterized and where comparator data exists.
MOLM-13 has also been applied in the evaluation of HDAC inhibitors including pracinostat, vorinostat, and BPR1J-340. The model sits within an Altogen Labs leukemia and lymphoma collection that includes HL-60, K562, MOLT4, Daudi, DOHH2, Granta519, H929, KARPAS 299, OPM2, Raji, Ramos, RL NHL, and the A20 and EL4 syngeneic murine models.
Supporting services include tissue and blood collection, histology, isolation of total protein or RNA, gene expression analysis, and full statistical treatment of all data.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, offering a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com